Attana invited to participate in Swiss Nordic Bio 2021
![](https://mb.cision.com/Public/16535/Cnct_FtrdImg_Dj_3267974/8a781244117f75fe_featured.jpg)
Attana has been invited to participate in Swiss Nordic Bio, a high-level partnering and investor conference for Swiss and Nordic actors in the biotech and pharma industries. Attending the conference are potential customers and strategic partners for Attana as well as potential future investors.
This year’s conference takes place between 10-11 February and will be solely digital. During the conference Attana will broadcast a 10-minute company presentation and participate in virtual one-on-one meetings. Attana will mainly focus on reaching out to and connecting with potential new customers but welcomes meetings with potential strategic partners and future investors.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
teodor.aastrup@attana.com
+ 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
About Attana
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com
Tags: